BIEL PPS HITS COPPER THIS YEAR, SILVER IN 2027, $1 in

New Post Public Reply Private Reply Replies (2) Message Board
Bielionaire
276
BIEL PPS HITS COPPER THIS YEAR, SILVER IN 2027, $1 in 2028
Based on the Electrome (currently US/Canada) partnership alone, and not counting Haleon as a possible future global partner. The recent 400% PPS surge outperformed 99.9% of all stocks.

BIEL begins generating revenue the moment Electrome ships commercial PAINKILLER™ units — which is already underway in 2026. The revenue clock has started. The first meaningful revenue shows up in 2026, with scale accelerating into 2027.

1. Electrome’s PAINKILLER™ Rollout = Immediate OEM Orders for BIEL
Electrome’s platform requires BIEL hardware in every kit:
ActiPatch
RecoveryRx
Veterinary PEMF modules

Electrome cannot ship a single PAINKILLER™ unit without purchasing BIEL hardware first.

Electrome has already:
begun VA deployments
begun clinical onboarding
begun pilot rollouts
secured Capital Factory backing
secured celebrity investor validation

Every one of these deployments requires hardware. Hardware shipments = BIEL invoices Electrome. This is already happening in 2026.

2. The VA Rollout Is Active — Not Theoretical
Electrome is already operating inside the U.S. Department of Veterans Affairs, the largest healthcare system in the country.

VA deployments = hardware shipments = BIEL revenue. This is not a future catalyst. It is a current revenue stream.

3. Electrome’s 2026 Commercial Launch = First Meaningful Revenue Wave
Electrome’s PAINKILLER™ platform launches in phases:

Phase 1 (2026): Early Commercial Rollout
VA deployments
Pilot clinics
Early adopter programs
Initial retail/consumer onboarding

This phase alone is modeled at $0.75M–$2.25M in OEM hardware revenue for BIEL. This is 2026 revenue, not 2027.

4. The 3,700-Store Retail Rollout Begins in 2026
Electrome’s retail strategy includes:
national pharmacy chains
consumer health retail
global distribution partners
Retail rollout = bulk hardware orders = BIEL revenue

This begins late 2026 and accelerates into 2027.

5. Electrome’s Rise Is BIEL’s Revenue Inflection Point
Electrome is executing the same model that made Medvi explode — but with:
FDA-cleared hardware
global distribution
VA deployments
celebrity investor validation
international adoption
a massive unmet need (chronic pain)
a platform that scales like software

This is why 2026 is the first real revenue year, and 2027 is the scale year.

6. Summary Timeline
Q1–Q2 2026
VA deployments begin - BIEL revenue starts

Q2–Q3 2026
PAINKILLER™ commercial rollout - OEM revenue ramps

Q3–Q4 2026
Retail onboarding + global distribution - bulk orders begin

2027
Full-scale OEM revenue across human, veterinary, and consumer health - multi-million-dollar annual run rate

Bottom Line:
BIEL is already generating revenue from Electrome in 2026.
The first meaningful wave is this year, and exponential scale begins in 2027.

PROFITABILITY IS WITHIN REACH
BIEL has already demonstrated how close it is - Q3 2021 profit:
$22,381 profit on $414,700 revenue (including $100K COVID relief).
With an ultra-lean model, sustained profitability is imminent.
Because BIEL’s operating costs are near zero, the revenue-to-profit conversion is extreme.

THE BIEL QUANTUM LEAP
If BIEL delivers $2.5M in net profit, it could command a $2.5B market cap — equivalent to $0.10 PPS at a P/E of 1000.

P/E ratios above 1,000 are common for early hypergrowth disruptors:
Amazon
Tesla
Salesforce
Zoom
Synaptics

BIEL fits this profile once profitability aligns with the Electrome narrative. And don’t forget: $40M tax-loss carryforward accelerates net profitability.

PPS PROJECTIONS (Key assumption: $2.5M rev ˜ $2.5M profit = $0.01 PPS, P/E = 1000 - this is realistic because BIEL’s OEM model has almost no overhead).

.001 — Technical breakout
.01 — Cash-flow positive (2026)
.10 — $2.5M profit (˜ $2.5M revenue, 2027)
$1.00 — After debt payoff + stock buyback (2028)

This timeline is based on the Electrome partnership alone, and could be accelerated (cut in half) if BIEL / Electrome announce a global contract with Haleon!

BioElectronics Corporation (BIEL) Stock Research Links

BIEL Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Stephanie L. Beiermann Shines in HR Consulting Honors

Updated Category News Views 114

Celebrating a Star in Payroll Optimization Ah, the name Stephanie L. Beiermann’s been making the rounds lately, catching eyes with her lauded expertise in payroll optimization and human resources. This recognition doesn’t come out of thin air—no, it’s anchored on a solid foundation of over 25 years of cutting through the fluff to sharpen operational edges. We’re...

Continue Reading
AvidXchange Acquisition Faces Fairness Investigation

Updated Category News Views 317

Unpacking the AvidXchange Turmoil Staring at the ticker tape feels like watching a drama unfold, and today it's all about AvidXchange Holdings, Inc. (NASDAQ: AVDX). Levi & Korsinsky, LLP has launched an investigation into the fairness of its acquisition, and let me tell you, when the suits start poking around, it means someone smells a rat. The deal in question? A buyout...

Continue Reading
Snowhawk Enters Telarus as Digital Demand Gets Serious

Updated Category News Views 7

Telarus just pulled another serious capital partner into the room, and that matters more than the usual law-firm victory lap. Snowhawk Partners has invested in the technology services distributor alongside Columbia Capital, which remains a long-standing partner. Nobody disclosed a valuation, ownership percentage, financing mix, or closing date. Annoying? Sure. But the...

Continue Reading
Lecanemab Shines in 5-Year Alzheimer's Study at CTAD

Updated Category News Views 172

Latest Lecanemab Results Turn Heads at CTAD 2026 The whispers buzzing out of the CTAD 2026 conference are about something promising for those in the trenches of Alzheimer's research: lecanemab. Yep, it's a name that's been bandied about before, and this time it's the long-term data doing the talking. The five-year results from Eisai and Biogen's lecanemab study are...

Continue Reading
Giovanni Recalde Sues County After False Report

Updated Category News Views 215

Justice and Reputation: A Mix-Up Costs Big When the cops screw up, sometimes they really take the cake. That's what Giovanni Recalde learned, the hard way, when his name got tangled in a mess related to a gambling operation he wasn't even a part of. Prince William County police pasted his name into their daily incident report last year like it was no big deal. But it...

Continue Reading
Amdocs Faces a Storm: Investor Alert as Legal Probe Begins

Updated Category News Views 64

Amdocs' Recent Crisis: What Investors Need to Know Lately, it seems Amdocs Limited (NASDAQ: DOX) has found itself knee-deep in a situation that could make seasoned investors cringe. November shone some harsh light on the company's operations, a move that’s attracted attention from Schall, Brown & Schwartz LLP (“SBS”), a name not exactly foreign to shareholder...

Continue Reading
OREF Opens $185,000 Research Grant Funding Cycle Today

Updated Category News Views 66

A hundred grand aimed at better graft science is not pocket change, but it is not a finished clinical program either. That distinction matters with the Orthopaedic Research and Education Foundation's newly opened $185,000 grant cycle. This is targeted, early-to-midstream research support: the sort of money that can produce usable data, sharpen a clinical question, and...

Continue Reading
Armada Moves up as Key Player in US SI Exports

Updated Category News Views 207

Pioneering New Grounds in Intelligence Infrastructure Hell of a move by Armada, stepping into the limelight as a priority team leader in the U.S. SI Exports Program. The whole gig is under the Department of Commerce's belt, pushing the frontier of America's Super Intelligence (SI) technology to buddies across the globe. It's like watching the next big blockbuster unfold...

Continue Reading
Intel Faces Class Action Over Alleged Securities Fraud

Updated Category News Views 122

Intel's Legal Predicament: Decoding the Lawsuit Saddle up, folks, because Intel (NASDAQ: INTC) has found itself tangled in legal vines again. This ain't their first rodeo, and probably won't be their last. We're looking at a hefty class action lawsuit rallying on claims that Intel misled investors with optimistic yarns about their health. SBS Law, waving the litigation...

Continue Reading
Lake Ridge's Strong Quarter Meets a Book Value Hit

Updated Category News Views 26

An $8.25-per-share securities markdown is the splinter in an otherwise sturdy third-quarter report from Lake Ridge Bancorp. The bank earned $9.8 million, or $4.97 per common share, for the quarter ended September 30, 2026. That is up from $9.0 million, or $4.59 per share, in the prior quarter and $7.7 million, or $3.94 per share, a year earlier. Those are not flimsy...

Continue Reading

Top 5 Most Recently Viewed Articles

Alliance Entertainment Expands Leadership with Robert Oram

Updated Category News Views 137

Alliance Entertainment Welcomes Robert Oram as EVP Alliance Entertainment Holding Corporation (NASDAQ: AENT) has made a significant addition to its leadership team with the appointment of Robert Oram as the Executive Vice President. This strategic move, announced recently, aims to bolster the company's efforts in expanding its home entertainment division. Oram, a veteran...

Continue Reading
Teradyne Inc: Navigating AI Growth in Semiconductor Testing

Updated Category News Views 155

Teradyne Inc (NASDAQ: TER) was one of those stocks that had traders buzzing back in 2023 when it saw gains up to 50% early in the year. That kind of momentum, especially outpacing the Philadelphia Semiconductor Index, had folks dreaming big. But reality hit later on as the market pulled back, reminding everyone that nothing lasts forever in this volatile game. Market...

Continue Reading
Transforming Landscapers' Cash Flow with Duranta's Payments

Updated Category News Views 163

Duranta Unveils a Game-Changer for Landscapers' Payments Duranta, the AI-driven platform for landscaping professionals, is set to reshape how landscaping businesses handle payments. Recently, they introduced an innovative feature that embeds secure payment links directly into customer invoices. This new function streamlines transaction methods for landscapers, making it...

Continue Reading
Analyzing Market Trends: The Case of WR Berkley Stock

Updated Category News Views 146

Understanding WR Berkley and Its Market Position WR Berkley Corporation (NYSE: WRB) has been making headlines recently due to its fluctuating short interest levels. The company, known for its diverse insurance offerings, recorded a significant rise in its short percent of float, now standing at 22.48%. This figure comes from its recent announcement that approximately 7.96...

Continue Reading
Timbercreek Financial to Host Q4 Results Call - Key Details Inside

Updated Category News Views 153

Timbercreek Financial's Upcoming Conference Call Timbercreek Financial (TSX: TF) is gearing up for an important conference call to discuss its financial results for the last quarter. This call is set for 1:00 p.m. (ET) on a Wednesday. The insights into the company’s performance will be revealed shortly after the markets close. Stakeholders and interested parties are...

Continue Reading